<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30177584</PMID>        <DateRevised>            <Year>2018</Year>            <Month>09</Month>            <Day>04</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">2005-9256</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Sep</Month>                        <Day>04</Day>                    </PubDate>                </JournalIssue>                <Title>Cancer research and treatment : official journal of Korean Cancer Association</Title>                <ISOAbbreviation>Cancer Res Treat</ISOAbbreviation>            </Journal>            <ArticleTitle>Early Decline in Left Ventricular Ejection Fraction Can Predict Trastuzumab-Related Cardiotoxicity in Patients with Breast Cancer: A Study Using 13 Years of Registry Data.</ArticleTitle>            <ELocationID EIdType="doi" ValidYN="Y">10.4143/crt.2018.262</ELocationID>            <Abstract>                <AbstractText Label="Purpose" NlmCategory="UNASSIGNED">While concerns regarding trastuzumab-related cardiac dysfunction (TRCD) in patients with breast cancer are increasing, there is a lack of evidence supporting the current recommendations for TRCD monitoring. We aimed to investigate the clinical predictors of TRCD in the adjuvant setting of human epidermal growth factor receptor 2-positive breast cancer patients.</AbstractText>                <AbstractText Label="Materials and Methods" NlmCategory="UNASSIGNED">From August 2003 to April 2016, consecutive 998 patients who were treated with adjuvant trastuzumab for breast cancer were retrospectively evaluated. TRCD was defined as a decrease ≥10% in left ventricular ejection fraction (LVEF), with a decline below the normal limit or symptomatic heart failure.</AbstractText>                <AbstractText Label="Results" NlmCategory="UNASSIGNED">Among 787 eligible patients who had complete data sets consisting of both baseline and follow-up assessment of left ventricular systolic function by echocardiography (mean age, 49.9±9.5 years), 58 (7.4%) developed TRCD. TRCD patients had lower baseline LVEF (63% [59-66] vs. 65% [61-68], p=0.016) and more frequently administered Adriamycin (98% vs. 89%, p=0.022) than those without TRCD. On follow-up echocardiography, a drop in LVEF ≥5% within the first 3 months was more frequent in TRCD patients (78.3% vs. 38.4%, p&lt;0.001). Regardless of baseline LVEF and Adriamycin treatment, a drop in LVEF ≥5% within the first 3 months of trastuzumab administration was strongly associated with the development of TRCD (adjusted hazard ratio, 45.1[17.0-127.6], p&lt;0.001).</AbstractText>                <AbstractText Label="Conclusion" NlmCategory="UNASSIGNED">The overall incidence of TRCD was 7.4% in Asian breast cancer patients treated with adjuvant trastuzumab. A decline in LVEF ≥5% within the first 3 months of trastuzumab initiation was strongly associated with TRCD development in patients with breast cancer.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Kim</LastName>                    <ForeName>Eun Kyoung</ForeName>                    <Initials>EK</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Cardiology, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Cho</LastName>                    <ForeName>Jinhyun</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Hematology-Oncology, Department of Medicine, Inha University Hospital, Inha University School of Medicine, Incheon, Korea.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Kim</LastName>                    <ForeName>Ji-Yeon</ForeName>                    <Initials>JY</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Chang</LastName>                    <ForeName>Sung-A</ForeName>                    <Initials>SA</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Cardiology, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Park</LastName>                    <ForeName>Sung-Ji</ForeName>                    <Initials>SJ</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Cardiology, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Choi</LastName>                    <ForeName>Jin Oh</ForeName>                    <Initials>JO</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Cardiology, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Lee</LastName>                    <ForeName>Sang Chol</ForeName>                    <Initials>SC</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Cardiology, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ahn</LastName>                    <ForeName>Jin Seok</ForeName>                    <Initials>JS</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Park</LastName>                    <ForeName>Seung Woo</ForeName>                    <Initials>SW</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Cardiology, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Im</LastName>                    <ForeName>Young-Hyuck</ForeName>                    <Initials>YH</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Jeon</LastName>                    <ForeName>Eun Seok</ForeName>                    <Initials>ES</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Cardiology, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Park</LastName>                    <ForeName>Yeon Hee</ForeName>                    <Initials>YH</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>09</Month>                <Day>04</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Korea (South)</Country>            <MedlineTA>Cancer Res Treat</MedlineTA>            <NlmUniqueID>101155137</NlmUniqueID>            <ISSNLinking>1598-2998</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Breast neoplasms</Keyword>            <Keyword MajorTopicYN="N">Cardiotoxicity</Keyword>            <Keyword MajorTopicYN="N">Left ventricular ejection fraction</Keyword>            <Keyword MajorTopicYN="N">Trastuzumab</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>05</Month>                <Day>04</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>09</Month>                <Day>03</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>9</Month>                <Day>5</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>9</Month>                <Day>5</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>9</Month>                <Day>5</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30177584</ArticleId>            <ArticleId IdType="pii">crt.2018.262</ArticleId>            <ArticleId IdType="doi">10.4143/crt.2018.262</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>